Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mapracorat 3% for ocular inflammation and pain after cataract surgery
NCT01591161Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Jul 2012
- Primary completion
- Jun 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ocular inflammation comparing Mapracorat with Vehicle (2 arms). Primary endpoints: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells at 8 days and Percentage of Participants With Grade 0 Pain at 8 days. Started Jul 2012; status: completed.
02
Drugs
mapracorat
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT01591161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01591161.